NURS 660 PSYCHOPHARMACOLOGY EXAM 4 | COMPLETE QUESTIONS WITH
EXPERT SOLUTIONS| 2026 LATEST UPDATED| A+
1. Brain region involved in selective attention.: Dorsal Anterior Cingulate Cortex
2. Brain region responsible for sustained attention.: Dorsolateral Prefrontal Cortex
3. Area linked to hyperactive symptoms in ADHD.: Prefrontal Motor Cortex
4. Region associated with impulsive behavior.: Orbitofrontal Cortex
5. Assessment tool for measuring sustained attention.: N-back Test
6. Neurotransmitter linked to attention regulation.: Norepinephrine
7. Key neurotransmitter involved in motivation and focus.: Dopamine
8. ADHD relates to signal clarity, not deficits.: Tuning Issue
9. Causes distractibility, disorganization, and fatigue.: Too Little Neurotransmitters
10. Can lead to mania or psychosis symptoms.: Too Much Neurotransmitters
11. Common symptom associated with low neurotransmitter levels.: Fatigue
12. Potential result of excessive neurotransmitter activity.: Panic Attacks
13. Enhances signal strength and connections in the brain.: Norepinephrine, imagine the telephone operator
14. Regulates inappropriate connections and reduces noise.: Dopamine, imagine the librarian
15. Stimulate norepinephrine to strengthen neural connections.: Alpha-2A receptors
16. Normal firing pattern supporting memory and learning.: Tonic firing
17. Burst firing aiding incremental learning, but risky.: Phasic firing
18. Amplify tonic norepinephrine and dopamine signaling.: Long-acting stimulants
,19. Cause quick dopamine bursts, risk of misuse.: Short-acting stimulants
20. Key area for reward processing and addiction.: Nucleus accumbens
21. Compulsive behavior due to hijacked reward circuitry.: Addiction
22. Behavior resulting from excessive phasic firing.: Erratic pleasure-seeking
23. Persistent pursuit of drugs despite negative consequences.: Compulsive substance
seeking
24. Brain pathways involved in motivation and pleasure.: Reward circuitry
25. Neural links crucial for executive functions and decision-making.: Connections in prefrontal cortex
26. A neurotransmitter involved in attention and arousal.: Norepinephrine
27. A neurotransmitter linked to reward and motivation.: Dopamine
28. Brain region for decision-making and impulse control.: Prefrontal Cortex
29Brain region associated with reward processing.: Nucleus Accumbens
30Amphetamine-based medication increasing dopamine and norepinephrine.: Adderall
31. Methylphenidate medication blocking dopamine re-uptake.: Ritalin
32. Medications enhancing brain activity for ADHD treatment.: Stimulants
33. Non-stimulant medication for ADHD treatment.: Strattera
34. Underlying condition that can worsen with stimulants.: Bipolar Disorder
35. Rare condition potentially triggered by stimulant use.: Raynaud's Phenomenon
36. Stimulants can cause modest blood pressure increase.: 2-4 mm Hg
37. Stimulants don't increase risk in healthy individuals.: Cardiac Death Risk
38. Increase of 3 to 8 mmHg noted with stimulants.: Systolic Blood Pressure
, 39. Increase of 2 to 14 mmHg noted with stimulants.: Diastolic Blood Pressure
40. Monitor blood pressure and heart rate long-term.: Stimulant Monitoring
41. Treated after mood symptoms in the hierarchy.: Anxiety Symptoms
42. Tics may worsen with stimulant medication.: Stimulant Exacerbation
43. Non-stimulant ADHD medication increasing norepinephrine and dopamine.: Strattera
44. Brain region involved in attention and decision-making.: Prefrontal cortex
45. Brain area associated with reward and addiction.: Nucleus accumbens
46. Enzyme metabolizing many psychiatric medications.: Cytochrome P450 2D6
47. Drugs increasing levels of another medication.: Strong inhibitors
48. Drugs decreasing levels of another medication.: Strong inducers
49. Antidepressant influencing Strattera metabolism through 2D6.: Prozac, Paxil, Bupropion
50. Non-stimulant ADHD treatment targeting alpha-2A receptors.: Guanfacine
51. Non-stimulant ADHD treatment with broader receptor effects.: Clonidine
52. Receptors enhancing signal strength in the brain.: Alpha-2A receptors
53. Increases absorption of guanfacine significantly.: High fat meal (think Guacomole is high fat content, guac/gua
54. Progressive neurodegenerative disorder with varying severity.: Alzheimer's disease
55. Protein accumulation unique to Alzheimer's disease.: Beta-Amyloid
56Protein abnormalities found in various dementias.: Tau Pathology
57Distinguished by tau pathology, lacks beta-amyloid.: Frontotemporal Dementia
58. Three A's of Alzheimers: Aphasia, apraxia, agnosia
EXPERT SOLUTIONS| 2026 LATEST UPDATED| A+
1. Brain region involved in selective attention.: Dorsal Anterior Cingulate Cortex
2. Brain region responsible for sustained attention.: Dorsolateral Prefrontal Cortex
3. Area linked to hyperactive symptoms in ADHD.: Prefrontal Motor Cortex
4. Region associated with impulsive behavior.: Orbitofrontal Cortex
5. Assessment tool for measuring sustained attention.: N-back Test
6. Neurotransmitter linked to attention regulation.: Norepinephrine
7. Key neurotransmitter involved in motivation and focus.: Dopamine
8. ADHD relates to signal clarity, not deficits.: Tuning Issue
9. Causes distractibility, disorganization, and fatigue.: Too Little Neurotransmitters
10. Can lead to mania or psychosis symptoms.: Too Much Neurotransmitters
11. Common symptom associated with low neurotransmitter levels.: Fatigue
12. Potential result of excessive neurotransmitter activity.: Panic Attacks
13. Enhances signal strength and connections in the brain.: Norepinephrine, imagine the telephone operator
14. Regulates inappropriate connections and reduces noise.: Dopamine, imagine the librarian
15. Stimulate norepinephrine to strengthen neural connections.: Alpha-2A receptors
16. Normal firing pattern supporting memory and learning.: Tonic firing
17. Burst firing aiding incremental learning, but risky.: Phasic firing
18. Amplify tonic norepinephrine and dopamine signaling.: Long-acting stimulants
,19. Cause quick dopamine bursts, risk of misuse.: Short-acting stimulants
20. Key area for reward processing and addiction.: Nucleus accumbens
21. Compulsive behavior due to hijacked reward circuitry.: Addiction
22. Behavior resulting from excessive phasic firing.: Erratic pleasure-seeking
23. Persistent pursuit of drugs despite negative consequences.: Compulsive substance
seeking
24. Brain pathways involved in motivation and pleasure.: Reward circuitry
25. Neural links crucial for executive functions and decision-making.: Connections in prefrontal cortex
26. A neurotransmitter involved in attention and arousal.: Norepinephrine
27. A neurotransmitter linked to reward and motivation.: Dopamine
28. Brain region for decision-making and impulse control.: Prefrontal Cortex
29Brain region associated with reward processing.: Nucleus Accumbens
30Amphetamine-based medication increasing dopamine and norepinephrine.: Adderall
31. Methylphenidate medication blocking dopamine re-uptake.: Ritalin
32. Medications enhancing brain activity for ADHD treatment.: Stimulants
33. Non-stimulant medication for ADHD treatment.: Strattera
34. Underlying condition that can worsen with stimulants.: Bipolar Disorder
35. Rare condition potentially triggered by stimulant use.: Raynaud's Phenomenon
36. Stimulants can cause modest blood pressure increase.: 2-4 mm Hg
37. Stimulants don't increase risk in healthy individuals.: Cardiac Death Risk
38. Increase of 3 to 8 mmHg noted with stimulants.: Systolic Blood Pressure
, 39. Increase of 2 to 14 mmHg noted with stimulants.: Diastolic Blood Pressure
40. Monitor blood pressure and heart rate long-term.: Stimulant Monitoring
41. Treated after mood symptoms in the hierarchy.: Anxiety Symptoms
42. Tics may worsen with stimulant medication.: Stimulant Exacerbation
43. Non-stimulant ADHD medication increasing norepinephrine and dopamine.: Strattera
44. Brain region involved in attention and decision-making.: Prefrontal cortex
45. Brain area associated with reward and addiction.: Nucleus accumbens
46. Enzyme metabolizing many psychiatric medications.: Cytochrome P450 2D6
47. Drugs increasing levels of another medication.: Strong inhibitors
48. Drugs decreasing levels of another medication.: Strong inducers
49. Antidepressant influencing Strattera metabolism through 2D6.: Prozac, Paxil, Bupropion
50. Non-stimulant ADHD treatment targeting alpha-2A receptors.: Guanfacine
51. Non-stimulant ADHD treatment with broader receptor effects.: Clonidine
52. Receptors enhancing signal strength in the brain.: Alpha-2A receptors
53. Increases absorption of guanfacine significantly.: High fat meal (think Guacomole is high fat content, guac/gua
54. Progressive neurodegenerative disorder with varying severity.: Alzheimer's disease
55. Protein accumulation unique to Alzheimer's disease.: Beta-Amyloid
56Protein abnormalities found in various dementias.: Tau Pathology
57Distinguished by tau pathology, lacks beta-amyloid.: Frontotemporal Dementia
58. Three A's of Alzheimers: Aphasia, apraxia, agnosia
